Of course that is your opinion .... I would expect nothing less than doom and gloom from a known MSB critic ... lol
You like many naysayers on here fail to acknowledge that the additional data from the 241 patients treated with Remestemcel-L through the FDA approved EAP will dramatically improve the BLA resubmission's chances .... you also fail to comprehend that the number 241 represents a figure far greater than any number of participants in any trial undertaken by Mesoblast for SR-aGVHD so one could form the view that Mesoblast have basically completed another trial anyway
MSB Price at posting:
84.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)